150 related articles for article (PubMed ID: 34875817)
21. The receptor activator of nuclear factor-kappaB ligand inhibitor osteoprotegerin is a bone-protective agent in a rat model of chronic renal insufficiency and hyperparathyroidism.
Padagas J; Colloton M; Shalhoub V; Kostenuik P; Morony S; Munyakazi L; Guo M; Gianneschi D; Shatzen E; Geng Z; Tan HL; Dunstan C; Lacey D; Martin D
Calcif Tissue Int; 2006 Jan; 78(1):35-44. PubMed ID: 16362459
[TBL] [Abstract][Full Text] [Related]
22. Bone loss in relation to serum levels of osteoprotegerin and nuclear factor-kappaB ligand: the Tromsø Study.
Jørgensen L; Vik A; Emaus N; Brox J; Hansen JB; Mathiesen E; Vestergaard P
Osteoporos Int; 2010 Jun; 21(6):931-8. PubMed ID: 19701599
[TBL] [Abstract][Full Text] [Related]
23. The effect of leptin replacement on parathyroid hormone, RANKL-osteoprotegerin axis, and Wnt inhibitors in young women with hypothalamic amenorrhea.
Foo JP; Polyzos SA; Anastasilakis AD; Chou S; Mantzoros CS
J Clin Endocrinol Metab; 2014 Nov; 99(11):E2252-8. PubMed ID: 25148234
[TBL] [Abstract][Full Text] [Related]
24. The role of insulin-like growth factor 1, receptor activator for nuclear factor κB ligand - osteoprotegerin system, interleukin 6 and 1β in post-transplantation bone metabolic disease in childhood.
Wędrychowicz A; Sztefko K; Majka M; Ratajczak MZ
Endokrynol Pol; 2013; 64(4):248-54. PubMed ID: 24002950
[TBL] [Abstract][Full Text] [Related]
25. Genetic variation in the RANKL/RANK/OPG signaling pathway is associated with bone turnover and bone mineral density in men.
Roshandel D; Holliday KL; Pye SR; Boonen S; Borghs H; Vanderschueren D; Huhtaniemi IT; Adams JE; Ward KA; Bartfai G; Casanueva F; Finn JD; Forti G; Giwercman A; Han TS; Kula K; Lean ME; Pendleton N; Punab M; Silman AJ; Wu FC; Thomson W; O'Neill TW;
J Bone Miner Res; 2010 Aug; 25(8):1830-8. PubMed ID: 20205168
[TBL] [Abstract][Full Text] [Related]
26. Imbalance of osteoprotegerin/receptor activator of nuclear factor-κB ligand and oxidative stress in patients with obstructive sleep apnea-hypopnea syndrome.
Ma XR; Wang Y; Sun YC
Chin Med J (Engl); 2019 Jan; 132(1):25-29. PubMed ID: 30628956
[TBL] [Abstract][Full Text] [Related]
27. Osteoprotegerin Levels Decrease in Abstinent Alcohol-Dependent Patients.
Malik P; von Gleissenthall G; Gasser RW; Moncayo R; Giesinger JM; Mechtcheriakov S
Alcohol Clin Exp Res; 2016 Jun; 40(6):1235-40. PubMed ID: 27061293
[TBL] [Abstract][Full Text] [Related]
28. Maintained malnutrition produces a progressive decrease in (OPG)/RANKL ratio and leptin levels in patients with anorexia nervosa.
Muñoz-Calvo MT; Barrios V; García de Alvaro MT; Lefort M; Méndez-Dávila C; Argente J; de la Piedra C
Scand J Clin Lab Invest; 2007; 67(4):387-93. PubMed ID: 17558893
[TBL] [Abstract][Full Text] [Related]
29. Serum osteoprotegerin and its ligand in cirrhotic patients referred for orthotopic liver transplantation: relationship with metabolic bone disease.
Monegal A; Navasa M; Peris P; Alvarez L; Pons F; Rodés J; Guañabens N
Liver Int; 2007 May; 27(4):492-7. PubMed ID: 17403189
[TBL] [Abstract][Full Text] [Related]
30. Biomarkers and cytokines of bone turnover: extensive evaluation in a cohort of patients with ankylosing spondylitis.
Taylan A; Sari I; Akinci B; Bilge S; Kozaci D; Akar S; Colak A; Yalcin H; Gunay N; Akkoc N
BMC Musculoskelet Disord; 2012 Oct; 13():191. PubMed ID: 23025387
[TBL] [Abstract][Full Text] [Related]
31. Effects of raloxifene therapy on circulating osteoprotegerin and RANK ligand levels in post-menopausal osteoporosis.
Fernández-García D; Muñoz-Torres M; Mezquita-Raya P; de la Higuera M; Alonso G; Reyes-García R; Ochoa AS; Ruiz-Requena ME; Luna JD; Escobar-Jiménez F
J Endocrinol Invest; 2008 May; 31(5):416-21. PubMed ID: 18560259
[TBL] [Abstract][Full Text] [Related]
32. Attenuation of WNT signaling by DKK-1 and -2 regulates BMP2-induced osteoblast differentiation and expression of OPG, RANKL and M-CSF.
Fujita K; Janz S
Mol Cancer; 2007 Oct; 6():71. PubMed ID: 17971207
[TBL] [Abstract][Full Text] [Related]
33. Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women.
Kim JG; Kim JH; Kim JY; Ku SY; Jee BC; Suh CS; Kim SH; Choi YM
Menopause; 2007; 14(5):913-8. PubMed ID: 17667143
[TBL] [Abstract][Full Text] [Related]
34. Osteoprotegerin, RANKL, and bone turnover in primary hyperparathyroidism: the effect of parathyroidectomy and treatment with alendronate.
Szymczak J; Bohdanowicz-Pawlak A
Horm Metab Res; 2013 Sep; 45(10):759-64. PubMed ID: 23888411
[TBL] [Abstract][Full Text] [Related]
35. Elevated serum levels of soluble receptor activator of nuclear factors-kappaB ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis (AS).
Kim HR; Lee SH; Kim HY
Rheumatology (Oxford); 2006 Oct; 45(10):1197-200. PubMed ID: 16567356
[TBL] [Abstract][Full Text] [Related]
36. Relationships between insulin-like growth factor-I (IGF-I) and OPG, RANKL, bone mineral density in healthy Chinese women.
Zhao HY; Liu JM; Ning G; Zhao YJ; Chen Y; Sun LH; Zhang LZ; Xu MY; Chen JL
Osteoporos Int; 2008 Feb; 19(2):221-6. PubMed ID: 17703270
[TBL] [Abstract][Full Text] [Related]
37. Does osteoprotegerin or receptor activator of nuclear factor-kappaB ligand mediate the association between bone and coronary artery calcification?
Bakhireva LN; Laughlin GA; Bettencourt R; Barrett-Connor E
J Clin Endocrinol Metab; 2008 May; 93(5):2009-12. PubMed ID: 18319315
[TBL] [Abstract][Full Text] [Related]
38. Implications of measuring soluble receptor activators of nuclear factor-kappaB ligand and osteoprotegerin in bone metabolism of elderly women.
Chiba Y; Onouchi T; Ikeda T; Adachi J; Tamura Y; Horiuchi T
Gerontology; 2009; 55(3):275-80. PubMed ID: 19158438
[TBL] [Abstract][Full Text] [Related]
39. The effect of dried plum on serum levels of receptor activator of NF-κB ligand, osteoprotegerin and sclerostin in osteopenic postmenopausal women: a randomised controlled trial.
Hooshmand S; Brisco JR; Arjmandi BH
Br J Nutr; 2014 Jul; 112(1):55-60. PubMed ID: 24780728
[TBL] [Abstract][Full Text] [Related]
40. Role of Wnt/β-catenin and RANKL/OPG in bone healing of diabetic Charcot arthropathy patients.
Folestad A; Ålund M; Asteberg S; Fowelin J; Aurell Y; Göthlin J; Cassuto J
Acta Orthop; 2015; 86(4):415-25. PubMed ID: 25811776
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
